Menu
Share this

PPD’s Reputation Ranked Best of all CROs in CenterWatch’s Global Survey of Clinical Research Sites

No. 1 for innovation in improving site relationships and use of
technology, data analytics

01 May 2013

RSS

WILMINGTON, N.C., (May 1, 2013) – Pharmaceutical Product Development, LLC (PPD) today announced that clinical research sites globally ranked the company No. 1 for reputation among all contract research organizations (CROs) in CenterWatch’s 2013 Global Investigative Site Relationship Survey.

PPD also ranked second on investigative sites’ evaluation of their clinical trial relationships with CROs. Overall, PPD was ranked in the top three CROs on all 36 relationship attributes that the questionnaire asked of clinical research professionals at investigative sites globally.

Not only did four of every five survey respondents say PPD had an excellent or good reputation, PPD also ranked best in “being an innovator in finding ways to improve its relationships with sites and using technology to make processes more efficient, [using] data analytics to help target where sites might have a potential issue,” according to The CenterWatch Monthly, which published the survey results today. “PPD uses its analytics to improve productivity and quality across all project functions, not just monitoring.”

Clinical research professionals at 2,032 global sites completed the biennial survey, the largest CenterWatch has conducted to measure the quality of working relationships between CROs and sites conducting clinical research.

“These survey results are a real testament to the quality of the staff at PPD,” said Paul Colvin, PPD’s executive vice president, global clinical development. “We work to hire, train and retain the best team in the industry. We feel that trust, accountability, performance and results are the basis of PPD’s strong reputation within the industry and the foundation of our relationships with our biopharmaceutical clients and our investigative sites.

“Investigative sites are critical partners in clinical research,” Colvin said. “And strong site relationships are vital to our efforts to bend the cost and time curve of drug discovery and development to help our clients deliver life-changing medical therapies to the market faster, more cost effectively and with the highest possible quality.”

Said Mike Wilkinson, executive vice president and chief information officer for PPD: “Technology and process innovation are fundamental to enhancing our strong relationships with investigative sites and reducing cycle times on behalf of our clients. Real-time data access and actionable analytics drive effective site selection, study start-up and performance improvement, ultimately enabling quicker decisions that increase efficiencies in managing clinical trials.”

PPD’s best ranking for industry reputation follows its top overall CRO ranking in 2011, the last time CenterWatch conducted the global survey. PPD was rated highest in multiple categories that year, including staff professionalism, good protocol design, study initiation, being organized and prepared, and setting realistic project timelines. PPD also was rated one of Europe’s top CROs in the 2010 CenterWatch European Site Survey.

Since 1994, CenterWatch has been a global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals, ranging from top sponsors and CROs to research sites and niche providers, as well as an engaged population of patients interested in clinical research and volunteering.

Contacts
Media:
Lee Kennedy
+1 919 456 5350
lee.kennedy@ppdi.com

Investors:
Luke Heagle
+1 910 558 7585
luke.heagle@ppdi.com

About PPD
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s CenterWatch survey results, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate and retain key personnel; competition in the outsourcing industry; compliance with drug development regulations; changes in the regulation of the drug development process; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; PPD’s ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to control SG&A spending; and rapid technological advances that make our services less competitive. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.

Upcoming Tradeshows and Speaker Events

29Mar17 DIA EuroMeeting

29 Mar. 2017 - 31 Mar. 2017

3Apr17 WRIB

03 Apr. 2017 - 07 Apr. 2017

3Apr17 GCC

03 Apr. 2017

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Site Map Legal Notices Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.

Google+